Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001 Celixir provides update on ongoing clinical programme with lead therapeutic candidate CLXR-001 First patient successfully dosed in cardiomyopathy study Stratford-upon-Avon, UK: July, 6 2019...

Celixir publishes positive study results for potential cancer gene therapies showing cancer cell reduction in colon and breast cancer cell lines Celixir publishes positive study results for potential cancer gene therapies showing cancer cell reduction in colon and breast cancer cell lines Promising cancer gene therapy programme using small...

Celixir announces US FDA approval of the IND application for cell therapy Heartcel Celixir announces US FDA approval of the IND application for cell therapy HeartcelTM FDA IND and UK MHRA CTA approval both achieved in H1 2018 Potentially pivotal heart failure trial of up to 250...

Celixir appoints Dr Mubasher Sheikh as Chairman of the Board Celixir appoints Dr Mubasher Sheikh as Chairman of the Board Dr Fiona Murray, CBE, Professor Gary Pisano, Conor Kehoe and Professor Sir Martin Evans also join Celixir's Board ...

CELIXIR: CTA approval for potentially pivotal HeartcelTM Phase IIb trial CTA approval for potentially pivotal HeartcelTM Phase IIb trial - Adult heart failure trial to complete in 2020 with potential market entry in 2021- Trial to be conducted at Imperial College...